Crescent Sterling Ltd. increased its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 4.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,309 shares of the medical research company’s stock after acquiring an additional 438 shares during the period. Amgen comprises 2.5% of Crescent Sterling Ltd.’s investment portfolio, making the stock its 12th biggest holding. Crescent Sterling Ltd.’s holdings in Amgen were worth $2,426,000 as of its most recent SEC filing.
Several other large investors have also added to or reduced their stakes in the business. Matrix Trust Co raised its stake in shares of Amgen by 306.2% in the fourth quarter. Matrix Trust Co now owns 459 shares of the medical research company’s stock worth $120,000 after purchasing an additional 346 shares during the last quarter. Aprio Wealth Management LLC grew its holdings in Amgen by 7.9% during the fourth quarter. Aprio Wealth Management LLC now owns 1,244 shares of the medical research company’s stock worth $324,000 after buying an additional 91 shares in the last quarter. Czech National Bank raised its position in Amgen by 6.5% in the 4th quarter. Czech National Bank now owns 116,548 shares of the medical research company’s stock valued at $30,377,000 after buying an additional 7,089 shares during the last quarter. Graypoint LLC lifted its stake in Amgen by 42.1% during the 4th quarter. Graypoint LLC now owns 7,339 shares of the medical research company’s stock valued at $1,913,000 after acquiring an additional 2,175 shares in the last quarter. Finally, HBW Advisory Services LLC lifted its stake in Amgen by 1.0% during the 4th quarter. HBW Advisory Services LLC now owns 8,559 shares of the medical research company’s stock valued at $2,231,000 after acquiring an additional 88 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.
Amgen Trading Down 0.7 %
Shares of Amgen stock opened at $262.23 on Monday. The company has a 50 day simple moving average of $279.10 and a two-hundred day simple moving average of $308.66. The firm has a market cap of $140.96 billion, a PE ratio of 33.58, a PEG ratio of 2.91 and a beta of 0.56. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96.
Amgen Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be given a $2.38 dividend. This is an increase from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a yield of 3.63%. Amgen’s payout ratio is presently 121.90%.
Wall Street Analyst Weigh In
AMGN has been the subject of several analyst reports. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Cantor Fitzgerald reissued an “overweight” rating and set a $405.00 target price on shares of Amgen in a research report on Tuesday, October 22nd. Citigroup reduced their target price on Amgen from $335.00 to $310.00 in a report on Wednesday, November 27th. Sanford C. Bernstein assumed coverage on Amgen in a report on Thursday, October 17th. They set an “outperform” rating and a $380.00 price target on the stock. Finally, Piper Sandler reduced their price objective on Amgen from $344.00 to $310.00 and set an “overweight” rating for the company in a research note on Thursday, January 2nd. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $314.91.
View Our Latest Stock Analysis on Amgen
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
See Also
- Five stocks we like better than Amgen
- Quiet Period Expirations Explained
- 3 Dividend Stocks with Growth Potential You Can’t Miss
- How to Plot Fibonacci Price Inflection Levels
- 2 Chinese EV Makers Setting Record Sales and Improving Margins
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Top 3 Preferred Stock ETFs Offering Stability and High Dividends
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.